BridgeBio Pharma, Inc. Revenue 2019–2025

Revenue Gross Profit Operating Income EBITDA Net Income EPS Shares Outstanding

BridgeBio Pharma, Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

BridgeBio Pharma, Inc. revenue for the quarter ending March 31, 2026 was 194.5 M, a 66.78% increase year-over-year.
BridgeBio Pharma, Inc. revenue for the twelve months ending March 31, 2026 was 542.4 M, a 146.43% increase year-over-year.
BridgeBio Pharma, Inc. annual revenue for 2025 was 502.1 M, a 126.26% increase from 2024.
BridgeBio Pharma, Inc. annual revenue for 2024 was 221.9 M, a 2285.27% increase from 2023.
BridgeBio Pharma, Inc. annual revenue for 2023 was 9.3 M, a 88.02% decrease from 2022.
BridgeBio Pharma, Inc. annual revenue for 2022 was 77.6 M.

Revenue

TRAILING 12 MONTHS · $B

QUARTERLY · $B

YEAR-OVER-YEAR GROWTH · %

BridgeBio Pharma, Inc. (BBIO) — Frequently Asked Questions

BridgeBio Pharma, Inc. (BBIO) is a publicly traded US company. It has a market capitalization of $12.99B. In fiscal 2025 it reported revenue of $502M. Explore BBIO's stock price, financial statements, earnings history, margins and key ratios below.

What is BridgeBio Pharma, Inc.'s market cap?

BridgeBio Pharma, Inc. (BBIO) has a market capitalization of $12.99B.

What is the BBIO stock price?

BBIO trades at $67.84 (+0.65% on the day).

How much revenue does BridgeBio Pharma, Inc. make?

BridgeBio Pharma, Inc. reported revenue of $502M in fiscal 2025.